ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs for the treatment of central nervous system disorders. The Company has five drug programs in clinical and preclinical development. Its three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, which is in Phase II clinical trials, and ACP-104 and ACP-103, both for the treatment of schizophrenia, which are expected to enter into Phase II clinical trials in 2004. The Company has retained worldwide commercialization rights to these drug candidates. It also has two preclinical programs for the development of drug candidates for neuropathic pain and glaucoma in collaboration with Allergan. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline.